3C Therapeutics receives NRC IRAP support for degrader-antibody conjugate research

On July 15, 2025, 3C Therapeutics was approved for financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop and characterize degrader-antibody conjugates using its TriCore platform.

The project focuses on building and evaluating candidate molecules for further research. 3C Therapeutics acknowledges the financial support of the Government of Canada.